Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nosis Bio Announces Development Candidate Nomination for Lead Fibrosis Program
Details : The nominated cell-targeted therapeutic selectively silences fibrotic drivers only in the pathogenic cells responsible for fibrosis disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 31, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Nosis, Daiichi Sankyo Partner for Cell-Targeted RNA Medicine Development
Details : The collaboration aims to leverage Nosis’ Connexa platform, to enable therapeutic access to extrahepatic cell types across multiple vital organs affected by chronic diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration